Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9368 | 0.92 | PAOX (0.55) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL25387214 | 0.92 | PAOX (0.55) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL14258632 | 0.91 | PAOX (0.46) | PAOXSIGMAR1MAPT | |
| SCHEMBL1619610 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL1403872 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL1404033 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL1403846 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL20231224 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL1619627 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL5880368 | 0.90 | PAOX (0.59) | PAOXSIGMAR1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667511-A2 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2025-12-24 | — | — | EP | claimed |
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2024-06-27 | — | — | US | claimed |
| CN-117915958-A | Dendritic structures as non-viral vectors in gene delivery | 蒂巴生物技术有限公司 | 2024-04-19 | — | — | CN | claimed |
| EP-4313170-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | Tiba Biotech LLC (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212838-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TIBA BIOTECH LLC (US) | 2022-10-06 | — | — | WO | claimed |
| CN-112612189-B | Positive photoresist developing solution for panel display | 福建省佑达环保材料有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-112612189-A | Positive photoresist developing solution for panel display | 福建省佑达环保材料有限公司 | 2021-04-06 | — | — | CN | claimed |
| CN-111905523-A | Composition for removing sulfur dioxide from flue gas, preparation method thereof and flue gas desulfurization method | 攀钢集团研究院有限公司 | 2020-11-10 | — | — | CN | claimed |
| CN-111905524-A | Flue gas desulfurizing agent, preparation method thereof and flue gas desulfurizing method | 攀钢集团研究院有限公司 | 2020-11-10 | — | — | CN | claimed |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2020-07-02 | — | — | US | claimed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | claimed |
| EP-0790986-B1 | ANILINE DERIVATIVES | ZENECA LTD (GB) | 1999-01-20 | — | — | EP | claimed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | claimed |
| US-5821246-A | USEFUL AS TYROSINE KINASE INHIBITORS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ZENECA LIMITED (GB) | 1998-10-13 | — | — | US | claimed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | claimed |
| EP-0790986-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-08-27 | — | — | EP | claimed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | claimed |
| EP-0493846-B1 | Multifunctional additive for lubricating oils | MINI RICERCA SCIENT TECNOLOG (IT) | 1994-02-23 | — | — | EP | claimed |
| EP-0493846-A1 | Multifunctional additive for lubricating oils | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1992-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207187-A1 | DENDRITIC ARCHITECTURES AS NONVIRAL VECTORS IN GENE DELIVERY | TLR3, TLR9, TLR6 | PAOX 2038/4885SIGMAR1 511/4885CHRM2 4805/4885 |
| US-20200207779-A2 | THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ALK, MET, TIE1 | PAOX 2160/4885SIGMAR1 4811/4885CHRM2 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.